J Ayurveda Integr Med. 2018 Nov 17. pii: S0975-9476(17)30287-5. doi: 10.1016/j.jaim.2018.01.003. [Epub ahead of print] In vitro and in vivo evaluation of pterostilbene for the management of diabetic complications. Dodda D1, Rama Rao A1, Veeresham C Abstract BACKGROUND:
Aldose
reductase (AR) and Advanced glycation end product (AGE) are known to
play important roles in the development of diabetic complications. The
inhibitors of AR and AGE would be potential agents for the prevention of
diabetic complications. OBJECTIVE:
The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end product (AGE) inhibitory potential of pterostilbene for its possible role in the treatment of diabetic complications such as cataract. MATERIALS AND METHODS:
The compound was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit the formation of AGEs. Anticataract activity of pterostilbene was demonstrated using sugar induced lens opacity model in isolated cattle lens. Further, the involvement of pterostilbene in galactosemia in rats was investigated by assessing the key markers in the polyol pathway and the results were compared with that of a potent AR inhibitor, fidarestat. RESULTS:
Pterostilbene exhibited inhibitory activity against RLAR and RKAR with IC50 values of 5.49 mg/ml (21.4 mM) and 6.40 mg/ml (25.02 mM), respectively. In sugar-induced lens opacity model, pterostilbene displayed a significant protective effect by preventing opacification and formation of polyols in cattle lens. Besides, the compound exhibited in vivo inhibition of galactitol accumulation in lens and sciatic nerves of galactose fed rats. CONCLUSION:
The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end product (AGE) inhibitory potential of pterostilbene for its possible role in the treatment of diabetic complications such as cataract. MATERIALS AND METHODS:
The compound was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit the formation of AGEs. Anticataract activity of pterostilbene was demonstrated using sugar induced lens opacity model in isolated cattle lens. Further, the involvement of pterostilbene in galactosemia in rats was investigated by assessing the key markers in the polyol pathway and the results were compared with that of a potent AR inhibitor, fidarestat. RESULTS:
Pterostilbene exhibited inhibitory activity against RLAR and RKAR with IC50 values of 5.49 mg/ml (21.4 mM) and 6.40 mg/ml (25.02 mM), respectively. In sugar-induced lens opacity model, pterostilbene displayed a significant protective effect by preventing opacification and formation of polyols in cattle lens. Besides, the compound exhibited in vivo inhibition of galactitol accumulation in lens and sciatic nerves of galactose fed rats. CONCLUSION:
The
results obtained in the study underline the potential of pterostilbene
as possible therapeutic agent against long-term diabetic complications. Copyright
© 2018 Transdisciplinary University, Bangalore and World Ayurveda
Foundation. Published by Elsevier B.V. All rights reserved. KEYWORDS:
Aldose reductase; Diabetic complications; Pterostilbene PMID:
- 30459079 DOI:
- 10.1016/j.jaim.2018.01.003
Free full text
Tässä kaihinvähentämisasiassa dieettiä muokkaamalla ja galaktoosiaineenvaihduntaa moduloimalla ei olla kovin pitkällä ihmiskunnan puolella.
Saattaa nimittäin olla laktoosin ja niin ollen galaktoosin runsaassa käytössä jotain osa syytä kaihin yleisyyteen maitoa runsaasti käyttävissä maissa. Vähälaktoosisten ruokien yleistymisen pitaisi siinä tapauksessa heijastua kaihin vähenemisessä.
Galaktoosia tosin on muissakin ruoissa kuin maidossa, esim viikunassa sitä on runsaasti ja papayassa, tomaatissa, monisas hedelmissä, kahvissakin sitä on. Pieni määrä galaktoosia ravinnosas on kutienkin edullista, mkuta se on määritä joita ei millään tavalla mitata tai noteerata. Täysi galaktoosinpuute ravinnossa saattaa heijastua punasolujen funktioon ja muutenkin asioihin joita ei yleensä mitata, esim solukalvojen glykokaliksin ominaisuuksia, luosnollisen immuniteetin puolen seikkoja.
Galaktoosi on sokeri, jonka soluun pääsyssä tarvitaan insuliinia. Mutta se on hanakasti solun ottama, ja menee glukoosia nopeammin soluun.
Galaktoosi on sokeri, jonka soluun pääsyssä tarvitaan insuliinia. Mutta se on hanakasti solun ottama, ja menee glukoosia nopeammin soluun.
Inga kommentarer:
Skicka en kommentar